114 related articles for article (PubMed ID: 17387004)
1. Kinetics of the time-dependent inactivation of CYP2D6 in cryopreserved human hepatocytes by methylenedioxymethamphetamine (MDMA).
Van LM; Swales J; Hammond C; Wilson C; Hargreaves JA; Rostami-Hodjegan A
Eur J Pharm Sci; 2007 May; 31(1):53-61. PubMed ID: 17387004
[TBL] [Abstract][Full Text] [Related]
2. The impact of experimental design on assessing mechanism-based inactivation of CYP2D6 by MDMA (Ecstasy).
Van LM; Heydari A; Yang J; Hargreaves J; Rowland-Yeo K; Lennard MS; Tucker GT; Rostami-Hodjegan A
J Psychopharmacol; 2006 Nov; 20(6):834-41. PubMed ID: 16478752
[TBL] [Abstract][Full Text] [Related]
3. Inactivation of CYP2D6 by methylenedioxymethamphetamine in different recombinant expression systems.
Van LM; Hargreaves JA; Lennard MS; Tucker GT; Rostami-Hodjegan A
Eur J Pharm Sci; 2007 Sep; 32(1):8-16. PubMed ID: 17574396
[TBL] [Abstract][Full Text] [Related]
4. Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine.
Heydari A; Yeo KR; Lennard MS; Ellis SW; Tucker GT; Rostami-Hodjegan A
Drug Metab Dispos; 2004 Nov; 32(11):1213-7. PubMed ID: 15328252
[TBL] [Abstract][Full Text] [Related]
5. The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans.
O'Mathúna B; Farré M; Rostami-Hodjegan A; Yang J; Cuyàs E; Torrens M; Pardo R; Abanades S; Maluf S; Tucker GT; de la Torre R
J Clin Psychopharmacol; 2008 Oct; 28(5):523-9. PubMed ID: 18794647
[TBL] [Abstract][Full Text] [Related]
6. Effect of sodium ozagrel on the activity of rat CYP2D6.
Wu H; Yu W; Huang L; Wang J; Tang X; Yang W; Liu Y; Yu H; Zhu D
Eur J Pharmacol; 2007 Nov; 573(1-3):55-9. PubMed ID: 17651725
[TBL] [Abstract][Full Text] [Related]
7. Sequential metabolism is responsible for diltiazem-induced time-dependent loss of CYP3A.
Zhao P; Lee CA; Kunze KL
Drug Metab Dispos; 2007 May; 35(5):704-12. PubMed ID: 17293381
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of time-dependent inactivation of CYP3A in cryopreserved human hepatocytes.
Zhao P; Kunze KL; Lee CA
Drug Metab Dispos; 2005 Jun; 33(6):853-61. PubMed ID: 15743977
[TBL] [Abstract][Full Text] [Related]
9. Mechanism-based inactivation of CYP2D6 by 5-fluoro-2-[4-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-piperazinyl]pyrimidine.
Palamanda JR; Casciano CN; Norton LA; Clement RP; Favreau LV; Lin C; Nomeir AA
Drug Metab Dispos; 2001 Jun; 29(6):863-7. PubMed ID: 11353755
[TBL] [Abstract][Full Text] [Related]
10. Influence of phenylalanine 120 on cytochrome P450 2D6 catalytic selectivity and regiospecificity: crucial role in 7-methoxy-4-(aminomethyl)-coumarin metabolism.
Keizers PH; Lussenburg BM; de Graaf C; Mentink LM; Vermeulen NP; Commandeur JN
Biochem Pharmacol; 2004 Dec; 68(11):2263-71. PubMed ID: 15498516
[TBL] [Abstract][Full Text] [Related]
11. Molecular docking and enzyme kinetic studies of dihydrotanshinone on metabolism of a model CYP2D6 probe substrate in human liver microsomes.
Zhou X; Wang Y; Or PM; Wan DC; Kwan YW; Yeung JH
Phytomedicine; 2012 May; 19(7):648-57. PubMed ID: 22541637
[TBL] [Abstract][Full Text] [Related]
12. Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA.
Yang J; Jamei M; Heydari A; Yeo KR; de la Torre R; Farré M; Tucker GT; Rostami-Hodjegan A
J Psychopharmacol; 2006 Nov; 20(6):842-9. PubMed ID: 16714321
[TBL] [Abstract][Full Text] [Related]
13. The effect of cimetidine on dextromethorphan O-demethylase activity of human liver microsomes and recombinant CYP2D6.
Madeira M; Levine M; Chang TK; Mirfazaelian A; Bellward GD
Drug Metab Dispos; 2004 Apr; 32(4):460-7. PubMed ID: 16680870
[TBL] [Abstract][Full Text] [Related]
14. Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6.
Shin JG; Soukhova N; Flockhart DA
Drug Metab Dispos; 1999 Sep; 27(9):1078-84. PubMed ID: 10460810
[TBL] [Abstract][Full Text] [Related]
15. Potent inhibition of cytochrome P-450 2D6-mediated dextromethorphan O-demethylation by terbinafine.
Abdel-Rahman SM; Marcucci K; Boge T; Gotschall RR; Kearns GL; Leeder JS
Drug Metab Dispos; 1999 Jul; 27(7):770-5. PubMed ID: 10383919
[TBL] [Abstract][Full Text] [Related]
16. The in vitro interaction of dexmedetomidine with human liver microsomal cytochrome P4502D6 (CYP2D6).
Rodrigues AD; Roberts EM
Drug Metab Dispos; 1997 May; 25(5):651-5. PubMed ID: 9152607
[TBL] [Abstract][Full Text] [Related]
17. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine.
Bertelsen KM; Venkatakrishnan K; Von Moltke LL; Obach RS; Greenblatt DJ
Drug Metab Dispos; 2003 Mar; 31(3):289-93. PubMed ID: 12584155
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes.
McGinnity DF; Berry AJ; Kenny JR; Grime K; Riley RJ
Drug Metab Dispos; 2006 Aug; 34(8):1291-300. PubMed ID: 16679385
[TBL] [Abstract][Full Text] [Related]
19. New cytochrome P450 2D6*56 allele identified by genotype/phenotype analysis of cryopreserved human hepatocytes.
Li L; Pan RM; Porter TD; Jensen NS; Silber P; Russo G; Tine JA; Heim J; Ring B; Wedlund PJ
Drug Metab Dispos; 2006 Aug; 34(8):1411-6. PubMed ID: 16679388
[TBL] [Abstract][Full Text] [Related]
20. Predictions of cytochrome P450-mediated drug-drug interactions using cryopreserved human hepatocytes: comparison of plasma and protein-free media incubation conditions.
Mao J; Mohutsky MA; Harrelson JP; Wrighton SA; Hall SD
Drug Metab Dispos; 2012 Apr; 40(4):706-16. PubMed ID: 22228749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]